INmune Bio Analyst Price Targets - Benzinga

INmune Bio Inc

INMBNASDAQ

Trade with Public

Trade with Public

$2.30

-0.03-1.29%

At close: Aug 31, 5:00 PM EST

$2.30

N/A

After Hours: 9:28 AM EST

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

INmune Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for INmune Bio (INMB).

Price Target Range — 5 Quarters

Analyst Consensus — 6 Analysts

5Buy

1Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$10Upside to Avg. PT+331.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 11, 2026	LUCID CAPITAL MARKETS	Elemer Piros	Upgrade	Neutral→Buy	$2→$9
Aug 12, 2025	Freedom Broker	Ilya Zubkov	PT Cut	Buy	$7→$4
Jul 3, 2025	Freedom Broker	Ilya Zubkov	Initiate	Buy	$7
Jul 2, 2025	Maxim Group	Jason McCarthy	PT Cut	Buy	$30→$8
Jul 1, 2025	BTIG	Thomas Shrader	Downgrade	Buy→Neutral	—
Jul 1, 2025	Scotiabank	George Farmer	Downgrade	Sector Outperform→Sector Underperform	$23→$1
Feb 13, 2025	Maxim Group	Jason McCarthy	PT Raise	Buy	$22→$30
Feb 11, 2025	Scotiabank	George Farmer	PT Raise	Sector Outperform	$22→$23
Oct 21, 2024	Alliance Global Partners	James Molloy	Initiate	Buy	$20
Sep 27, 2024	Raymond James	—	Initiate	Outperform	$18
Aug 22, 2024	Scotiabank	George Farmer	Initiate	Sector Outperform	$22

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
LUCID CAPITAL MARKETS Upgrades INmune Bio to Buy, Raises Price Target to $9

LUCID CAPITAL MARKETS analyst Elemer Piros upgrades INmune Bio (NASDAQ:INMB) from Neutral to Buy and raises the price target from $2 to $9.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on INmune Bio, Lowers Price Target to $8

Maxim Group analyst Jason McCarthy maintains INmune Bio (NASDAQ:INMB) with a Buy and lowers the price target from $30 to $8.

Benzinga Newsdesk

This Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Avi Kapoor

PRO
BTIG Downgrades INmune Bio to Neutral

BTIG analyst Thomas Shrader downgrades INmune Bio (NASDAQ:INMB) from Buy to Neutral.

Benzinga Newsdesk

PRO
Scotiabank Downgrades INmune Bio to Sector Underperform, Lowers Price Target to $0.6

Scotiabank analyst George Farmer downgrades INmune Bio (NASDAQ:INMB) from Sector Outperform to Sector Underperform and lowers the price target from $23 to $0.6.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on INmune Bio, Raises Price Target to $30

Maxim Group analyst Jason McCarthy maintains INmune Bio (NASDAQ:INMB) with a Buy and raises the price target from $22 to $30.

Benzinga Newsdesk